Rapport Therapeutics, Inc. — Form 8-K
Filed October 20, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Rapport Therapeutics announced positive topline results from a Phase 2 trial of RAP-219 in 253 adults with acute bipolar mania (253 enrolled, 126 RAP-219 vs. 127 placebo). The trial met its primary endpoint with a statistically significant 3.1-point placebo-adjusted improvement in YMRS total score at Week 3 (p=0.045; RAP-219 mean reduction 15.4 points vs. placebo 12.3 points) and secondary endpoint with 0.4-point CGI-BP mania severity improvement (p=0.024). RAP-219 was well-tolerated with all TEAEs mild/moderate, 3.2% discontinuation due to AEs (vs. 0.8% placebo), and notably absent the somnolence, akathisia, and extrapyramidal symptoms typical of current bipolar drugs. The company plans an End-of-Phase 2 FDA meeting in Q1 2027 and Phase 3 initiation in H2 2027.
Why this rating
Phase 2 proof-of-concept in lead asset justifies Phase 3 advancement. Company has $436.1M cash (158% of market cap) through H2 2029. Material near-term catalyst de-risks pipeline and supports valuation inflection if Phase 3 succeeds.
Price action (we called it positive)
at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 20, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.